Literature DB >> 1405041

The effect of nilvadipine, a dihydropyridine type calcium channel blocker, on local cerebral blood flow in rats.

Y Furuichi1, S Takakura, H Satoh, J Mori, M Kohsaka.   

Abstract

The effect of nilvadipine, a dihydropyridine type calcium channel blocker, on local cerebral blood flow (lCBF) was investigated using the autoradiographic iodo[14C]antipyrine technique in rats. In control rats, lCBF in cortical areas and in the superior colliculus and inferior colliculus was higher than that in the hippocampus, septal nucleus, globus pallidus and substantia nigra. Nilvadipine (32 micrograms/kg, i.v.) increased lCBF in all structures (significantly in 11 of 21 structures) in spite of a 33% reduction in mean arterial blood pressure. These results confirm that nilvadipine has the ability to increase cerebral blood flow.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1405041     DOI： 10.1254/jjp.58.457

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN： 0021-5198


  5 in total

Review 1.  Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina.

Authors:  R N Brogden; D McTavish
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

2.  Therapeutic effects of nilvadipine on rat focal cerebral ischemia.

Authors:  Y Li; S Kawamura; N Yasui; M Shirasawa; H Fukasawa
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

3.  The effect of nilvadipine on bloodflow in the dorsal pedis artery in type 2 diabetic patients--a study using duplex Doppler ultrasonography.

Authors:  H Sone; Y Okuda; M Mizutani; Y Kawakami; C Bannai; K Yamashita
Journal:  Postgrad Med J       Date:  1995-10       Impact factor: 2.401

4.  Evaluation of the Effect of Hypercapnia on Vascular Function in Normal Tension Glaucoma.

Authors:  B Quill; E Henry; E Simon; C J O'Brien
Journal:  Biomed Res Int       Date:  2015-10-18       Impact factor: 3.411

5.  NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease.

Authors:  Brian Lawlor; Sean Kennelly; Sarah O'Dwyer; Fiona Cregg; Cathal Walsh; Robert Coen; Rose Anne Kenny; Robert Howard; Caroline Murphy; Jessica Adams; Leslie Daly; Ricardo Segurado; Siobhan Gaynor; Fiona Crawford; Michael Mullan; Ugo Lucca; Rita Banzi; Florence Pasquier; Laetitia Breuilh; Matthias Riepe; Janos Kalman; Anders Wallin; Anne Borjesson; William Molloy; Magda Tsolaki; Marcel Olde Rikkert
Journal:  BMJ Open       Date:  2014-10-09       Impact factor: 2.692
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.